首页> 美国卫生研究院文献>other >Success of an International Learning Healthcare System in Hematopoietic Cell Transplantation: the American Society of Blood and Marrow Transplantation Clinical Case Forum
【2h】

Success of an International Learning Healthcare System in Hematopoietic Cell Transplantation: the American Society of Blood and Marrow Transplantation Clinical Case Forum

机译:国际学习医疗系统在造血细胞移植中的成功:美国血液和骨髓移植学会临床病例论坛

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The ASBMT Clinical Case Forum (CCF) was launched in 2014 as an online secure tool to enhance interaction and communication among hematopoietic cell transplantation (HCT) professionals worldwide through the discussion of challenging clinical care issues. After 14 months, we reviewed clinical and demographical data on cases posted in the CCF from 1/29/2014 to 3/18/2015. A total of 137 cases were posted during the study period. Ninety-two cases (67%) were allogeneic HCT, 29 (21%) autologous HCT and in 16 (12%) the type of transplant (auto vs. allo) was still under consideration. The diseases most frequently discussed included non-Hodgkin lymphoma (NHL; n = 30, 22%), acute myeloid leukemia (AML; n = 23, 17%) and multiple myeloma (MM; n = 20, 15%). When compared with the US transplant activity reported by the US Department of Health and Human Services, NHL and acute lymphoblastic leukemia cases were overrepresented in the CCF while myeloma was underrepresented (P < 0.001). A total of 259 topics were addressed in the CCF with a median of two topics/case (range 1-6). Particularly common topics included whether transplant was indicated (n = 57, 41%), conditioning regimen choice (n = 44, 32%), and post-HCT complications after day 100 (n = 43, 31%). The ASBMT CCF is a successful tool for collaborative discussion of complex cases in the HCT community worldwide and may allow identification of areas of controversy or unmet need from clinical, educational and research perspectives.
机译:ASBMT临床案例论坛(CCF)于2014年启动,是一种在线安全工具,可通过讨论具有挑战性的临床护理问题来增强全球造血细胞移植(HCT)专业人员之间的互动和交流。 14个月后,我们审查了2014年1月29日至2015年3月18日在CCF中发布的病例的临床和人口统计学数据。在研究期间,共发布了137例案例。异基因HCT有92例(67%),自体HCT有29例(21%),而16例(12%)仍在考虑移植类型(自体与异体)。讨论最频繁的疾病包括非霍奇金淋巴瘤(NHL; n = 30,22%),急性髓性白血病(AML; n = 23,17%)和多发性骨髓瘤(MM; n = 20,15%)。与美国卫生和公众服务部报告的美国移植活动相比,CCF中NHL和急性淋巴细胞白血病病例的代表过多,而骨髓瘤的代表性不足(P <0.001)。 CCF共解决了259个主题,中位数为两个主题/案例(范围1-6)。特别常见的主题包括是否需要移植(n = 57,41%),选择治疗方案(n = 44,32%)以及第100天后HCT后并发症(n = 43,31%)。 ASBMT CCF是成功讨论全球HCT社区中复杂案件的成功工具,并且可以从临床,教育和研究的角度确定有争议的领域或未满足的需求。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号